Sitagliptin Metformin Duo Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
MFDS item code 202200909 · Approved 2022.03.02
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used along with dietary and exercise modifications to help control blood sugar in patients with type 2 diabetes. It is utilized when initial diabetes medication therapy is inadequate for blood sugar control when used alone and is given as an alternative therapy when treatment with metformin or sitagliptin alone is insufficient. Additionally, it enhances blood sugar control when combined with metformin, sulfonylureas, thiazolidinediones, or insulin when blood sugar remains difficult to manage. This medication aids in improving blood sugar control across various treatment stages.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).
This medication is a combination product containing sitagliptin and metformin and is used for blood sugar control in patients with type 2 diabetes. While taking this medication, severe allergic reactions may occur; therefore, if symptoms such as rash, hives, difficulty breathing, or swelling of the face or lips appear, discontinue use immediately and consult a physician. If symptoms of acute pancreatitis such as severe abdominal pain, vomiting, or nausea occur, stop taking this medication immediately and visit a hospital. This medication should not be administered to patients with severely impaired renal function or those suffering from severe infections, dehydration, acute heart failure, or acute myocardial infarction, and it should be temporarily discontinued before and after procedures requiring iodinated contrast agents. It is advisable for pregnant women or those who may become pregnant, as well as nursing mothers, not to use this medication. This medication can cause a rare but serious metabolic disorder known as lactic acidosis; therefore, if symptoms such as muscle pain, fatigue, difficulty breathing, abdominal pain, or unusual changes in consciousness occur, seek medical attention immediately. Hypoglycemia symptoms may manifest if blood sugar drops too low; thus, be especially cautious about these symptoms if taking insulin or sulfonylureas concurrently and consult a physician if necessary to adjust the dose. Regular monitoring of renal function, blood tests, and vitamin B12 levels is essential during the use of this medication. Be cautious of blood sugar control being affected by vigorous exercise, irregular eating, or interactions with other medications. If surgery is planned, discontinue this medication 48 hours prior to the procedure and restart only after confirming normal renal function post-surgery. Consumption of alcohol may increase the risk of lactic acidosis; therefore, excessive drinking should be avoided during treatment. Common side effects associated with this medication include diarrhea, nausea, vomiting, headache, and upper respiratory infection, while severe side effects may include joint pain or skin rash, and blistering diseases. If these symptoms arise, it is important to consult with a physician to receive appropriate measures. Elderly patients may have a higher risk of decreased renal function and thus require careful adjustment of this medication's dosage and monitoring of renal function.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air from entering, at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's efficacy over a long period.
Pink oval film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.